onc Videos

Videos

Videos

Talquetamab Plus Daratumumab Yields Durable Responses for Patients With R/R Multiple Myeloma

06/12/2023

Bhagirathbhai R. Dholaria, MBBS, highlights findings from the TRiMM-2 trial, which demonstrated that the combination of talquetamab and daratumumab was safe and effective for patients with R/R multiple myeloma.

Bhagirathbhai R. Dholaria, MBBS,...

06/12/2023

Oncology

Dorota Goplen, MD, Haukeland University Hospital

Videos

Sequential Bortezomib Plus Temozolomide is Safe, Effective for Recurrent Glioblastoma

06/12/2023

Dorota Goplen, MD, Haukeland University Hospital, Bergen, Norway, discusses results from a phase 1b/2 BORTEM-17 study evaluating the efficacy of sequential treatment with bortezomib and temozolomide for patients with glioblastoma and...

Dorota Goplen, MD, Haukeland...

06/12/2023

Oncology

Jason Luke, MD, UPMC Hillman Cancer Center

Videos

Adjuvant Pembrolizumab for Stage IIB/IIC Melanoma

06/12/2023

At the 2023 ASCO Annual Meeting, Jason Luke, MD, shares results from the protocol-specified final distant metastasis-free survival analysis of KEYNOTE-716, evaluating adjuvant pembrolizumab among patients with stage IIIB and IIIC resected...

At the 2023 ASCO Annual Meeting,...

06/12/2023

Oncology

Videos

Assessment of Real World Avelumab Uptake for Patients with Urothelial Carcinoma

06/09/2023

At the 2023 ASCO Annual Meeting, Helen Moon, MD, discusses results from a study investigating the real world response rates of patients with urothelial carcinoma treated with first-line platinum-based chemotherapy, to assess the uptake of...

At the 2023 ASCO Annual Meeting,...

06/09/2023

Oncology

Yutaka Yamamoto, Kumamoto University Hospital

Videos

Pertuzumab Retreatment Improves OS in HER2-Positive Locally Advanced or Metastatic Breast Cancer

06/08/2023

Yutaka Yamamoto, MD, discusses OS results from the phase 3 PRECIOUS trial evaluating pertuzumab retreatment in patients with HER2-positive locally advanced or metastatic breast cancer.

Yutaka Yamamoto, MD, discusses...

06/08/2023

Oncology

Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute

Videos

Sacituzumab Govetican Improves Survival Outcomes For Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer

06/08/2023

Sara Tolaney shares the final overall survival analysis of the phase 3 TROPiCS-02 trial, evaluating sacituzumab govitecan in pretreated metastatic HR-positive breast cancer, which was presented at the 2023 ASCO Annual Meeting

Sara Tolaney shares the final...

06/08/2023

Oncology

Videos

Split-Dose R-CHOP Treatment for Older Patients With Diffuse Large B-Cell Lymphoma

06/07/2023

At the 2023 American Society of Clinical Oncology Annual Meeting, Nirav Niranjan Shah, MD, shared findings from a phase 2 trial of split-dose R-CHOP for older patients with DLBCL.

At the 2023 American Society of...

06/07/2023

Oncology

Recent News

News

Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer

11/18/2024

Stephanie Holland ;

According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.

According to results from a...

11/18/2024

Oncology

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology